JP2023549357A5 - - Google Patents

Info

Publication number
JP2023549357A5
JP2023549357A5 JP2023528230A JP2023528230A JP2023549357A5 JP 2023549357 A5 JP2023549357 A5 JP 2023549357A5 JP 2023528230 A JP2023528230 A JP 2023528230A JP 2023528230 A JP2023528230 A JP 2023528230A JP 2023549357 A5 JP2023549357 A5 JP 2023549357A5
Authority
JP
Japan
Prior art keywords
acid sequence
nucleic acid
seq
genetically modified
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023528230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549357A (ja
JP7642809B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059146 external-priority patent/WO2022104062A1/en
Publication of JP2023549357A publication Critical patent/JP2023549357A/ja
Publication of JP2023549357A5 publication Critical patent/JP2023549357A5/ja
Priority to JP2025028775A priority Critical patent/JP2025098002A/ja
Application granted granted Critical
Publication of JP7642809B2 publication Critical patent/JP7642809B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023528230A 2020-11-12 2021-11-12 ジストロフィン遺伝子内の認識配列に特異性を有する遺伝子操作されたメガヌクレアーゼ Active JP7642809B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025028775A JP2025098002A (ja) 2020-11-12 2025-02-26 ジストロフィン遺伝子内の認識配列に特異性を有する遺伝子操作されたメガヌクレアーゼ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063113131P 2020-11-12 2020-11-12
US63/113,131 2020-11-12
US202163233664P 2021-08-16 2021-08-16
US63/233,664 2021-08-16
PCT/US2021/059146 WO2022104062A1 (en) 2020-11-12 2021-11-12 Engineered meganucleases having specificity for recognition sequences in the dystrophin gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025028775A Division JP2025098002A (ja) 2020-11-12 2025-02-26 ジストロフィン遺伝子内の認識配列に特異性を有する遺伝子操作されたメガヌクレアーゼ

Publications (3)

Publication Number Publication Date
JP2023549357A JP2023549357A (ja) 2023-11-24
JP2023549357A5 true JP2023549357A5 (cg-RX-API-DMAC10.html) 2024-11-20
JP7642809B2 JP7642809B2 (ja) 2025-03-10

Family

ID=78844897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023528230A Active JP7642809B2 (ja) 2020-11-12 2021-11-12 ジストロフィン遺伝子内の認識配列に特異性を有する遺伝子操作されたメガヌクレアーゼ
JP2025028775A Pending JP2025098002A (ja) 2020-11-12 2025-02-26 ジストロフィン遺伝子内の認識配列に特異性を有する遺伝子操作されたメガヌクレアーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025028775A Pending JP2025098002A (ja) 2020-11-12 2025-02-26 ジストロフィン遺伝子内の認識配列に特異性を有する遺伝子操作されたメガヌクレアーゼ

Country Status (13)

Country Link
US (4) US11753630B2 (cg-RX-API-DMAC10.html)
EP (2) EP4244342B1 (cg-RX-API-DMAC10.html)
JP (2) JP7642809B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250099412A (cg-RX-API-DMAC10.html)
CN (3) CN116783293B (cg-RX-API-DMAC10.html)
AU (1) AU2021380823B2 (cg-RX-API-DMAC10.html)
CA (1) CA3172481A1 (cg-RX-API-DMAC10.html)
DK (1) DK4244342T3 (cg-RX-API-DMAC10.html)
ES (1) ES3072243T3 (cg-RX-API-DMAC10.html)
FI (1) FI4244342T3 (cg-RX-API-DMAC10.html)
IL (2) IL302733B2 (cg-RX-API-DMAC10.html)
MX (1) MX2023005496A (cg-RX-API-DMAC10.html)
WO (1) WO2022104062A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229299A1 (en) * 2014-03-12 2016-09-22 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
WO2023015304A1 (en) * 2021-08-05 2023-02-09 Insmed Incorporated Adeno-associated virus particles and methods of use thereof
IL317740A (en) * 2022-06-30 2025-02-01 Sarepta Therapeutics Inc Methods for treating muscular dystrophy
CN121311497A (zh) 2023-04-14 2026-01-09 精密生物科学公司 肌肉特异性表达盒
WO2024216116A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
AU2025209190A1 (en) * 2024-01-16 2026-07-16 Astellas Gene Therapies, Inc. Muscle selective hybrid regulatory combinations and methods of use thereof for the treatment of myotonic dystrophy type 1

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2009001159A1 (en) 2007-06-25 2008-12-31 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
US9273296B2 (en) * 2008-09-08 2016-03-01 Cellectis Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
EP2569424A1 (en) * 2010-05-12 2013-03-20 Cellectis Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
EP3683319A1 (en) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
SI3581654T1 (sl) 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
AU2015229299A1 (en) * 2014-03-12 2016-09-22 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
TWI864340B (zh) 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
US12214054B2 (en) * 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
JP7256739B2 (ja) 2016-09-07 2023-04-12 サンガモ セラピューティクス, インコーポレイテッド 肝臓遺伝子のモジュレーション
KR20230010826A (ko) * 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
EP3585899A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
CN110997923B (zh) * 2017-03-17 2024-01-02 全国儿童医院研究所 腺相关病毒载体递送肌肉特异性微肌营养不良蛋白以治疗肌营养不良症
EP4269596A3 (en) * 2017-04-21 2024-02-14 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the pcsk9 gene
MX2021001070A (es) 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
EP3898661A1 (en) * 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria

Similar Documents

Publication Publication Date Title
JP2022091989A5 (cg-RX-API-DMAC10.html)
JP2024083479A5 (cg-RX-API-DMAC10.html)
JP2022516130A5 (cg-RX-API-DMAC10.html)
JP2023543803A5 (cg-RX-API-DMAC10.html)
JP2023532663A5 (cg-RX-API-DMAC10.html)
JP2023516226A5 (cg-RX-API-DMAC10.html)
JP2022528010A5 (cg-RX-API-DMAC10.html)
JP2018138049A5 (cg-RX-API-DMAC10.html)
JP2023544683A5 (cg-RX-API-DMAC10.html)
JP2021518139A5 (cg-RX-API-DMAC10.html)
JP2014012022A5 (cg-RX-API-DMAC10.html)
JP2020517255A5 (cg-RX-API-DMAC10.html)
JP2021510528A5 (cg-RX-API-DMAC10.html)
JP2020508685A5 (cg-RX-API-DMAC10.html)
RU2018137279A (ru) Новые минимальные utr-последовательности
JP2025060848A5 (cg-RX-API-DMAC10.html)
JP2022066336A5 (cg-RX-API-DMAC10.html)
JP2008545406A5 (cg-RX-API-DMAC10.html)
JP2023533417A5 (cg-RX-API-DMAC10.html)
JPWO2020218419A5 (cg-RX-API-DMAC10.html)
JP2012515557A5 (cg-RX-API-DMAC10.html)
JP2025504898A5 (cg-RX-API-DMAC10.html)
JP2023525960A5 (cg-RX-API-DMAC10.html)
JP2008515450A5 (cg-RX-API-DMAC10.html)
JP2024503091A5 (cg-RX-API-DMAC10.html)